Company Filing History:
2 out of 906 
1 out of 1,458 
1 out of 272 
Years Active: 2012-2016
Title: Jim Jung-Ching Lin: Innovator in Colorectal Cancer Research
Introduction
Jim Jung-Ching Lin is a notable inventor based in Iowa City, IA (US). He has made significant contributions to the field of cancer research, particularly in the prevention of colorectal cancer. With a total of 2 patents, Lin's work focuses on innovative methods and compositions that aim to improve patient outcomes.
Latest Patents
Lin's latest patents include groundbreaking methods for the chemoprevention of colorectal cancer. One patent discloses a method for preventing colorectal cancer in patients possessing the human tropomyosin isoform TC22. This method involves detecting the serum protein concentration of TC22 in a patient and administering a therapeutically effective amount of a chemotherapeutic composition that reduces the level of TC22. The chemotherapeutic compounds mentioned include sulfasalazine, 5-amino-2-hydroxybenzoic acid, osalazine, and balsalazide.
Another patent introduces a novel isoform of tropomyosin, referred to as TC22. This isoform is closely related to epithelial human tropomyosin (hTM) and is particularly significant in the context of tumor tissues and dysfunction of the alimentary canal. The patent highlights the diagnostic and therapeutic uses of TC22, including the development of specific antibodies and mimics for its application in medical diagnostics.
Career Highlights
Throughout his career, Jim Jung-Ching Lin has been associated with prestigious institutions such as the University of Iowa Research Foundation and Rutgers, the State University of New Jersey. His work has been instrumental in advancing the understanding of colorectal cancer and its prevention.
Collaborations
Lin has collaborated with various professionals in his field, including Kiron M Das, to further enhance the impact of his research and innovations.
Conclusion
Jim Jung-Ching Lin's contributions to colorectal cancer research through his patents and collaborations underscore his commitment to improving patient care. His innovative approaches continue to pave the way for advancements in cancer prevention and treatment.